Specific activity of cyclin-dependent kinase I is a new potential predictor of tumour recurrence in stage II colon cancer

[1]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[2]  L. V. van't Veer,et al.  Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[4]  Elizabeth M Webber,et al.  Oncotype DX tumor gene expression profiling in stage II colon cancer , 2010, PLoS currents.

[5]  J. Fregnani,et al.  Evaluation of cell cycle protein expression in gastric cancer: cyclin B1 expression and its prognostic implication. , 2010, Human pathology.

[6]  O. Timofeev,et al.  Cdc25 Phosphatases Are Required for Timely Assembly of CDK1-Cyclin B at the G2/M Transition* , 2010, The Journal of Biological Chemistry.

[7]  Sabine Tejpar,et al.  Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery , 2010, The oncologist.

[8]  L. Komuves,et al.  Ubiquitin hydrolase Dub3 promotes oncogenic transformation by stabilizing Cdc25A , 2010, Nature Cell Biology.

[9]  Sabine Tejpar,et al.  Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  D. Sargent,et al.  Revised TN categorization for colon cancer based on national survival outcomes data. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  E. Van Cutsem,et al.  Primary colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  H. Samonigg,et al.  Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors. , 2009, The Journal of molecular diagnostics : JMD.

[13]  M. Barbacid,et al.  Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.

[14]  H. Putter,et al.  Validation study of the prognostic value of cyclin-dependent kinase (CDK)-based risk in Caucasian breast cancer patients , 2009, British Journal of Cancer.

[15]  Achim Zeileis,et al.  Generalized Maximally Selected Statistics , 2008, Biometrics.

[16]  M. Choti,et al.  Urgent need for a new staging system in advanced colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  K. Kozak,et al.  The impact of T and N stage on long‐term survival of rectal cancer patients in the community , 2008, Journal of surgical oncology.

[18]  D. Sargent,et al.  Prognostic Significance of Defective Mismatch Repair and BRAF V600E in Patients with Colon Cancer , 2008, Clinical Cancer Research.

[19]  R. Houlston,et al.  Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis , 2008, Gut.

[20]  Y. Miyoshi,et al.  Determination of the specific activity of CDK1 and CDK2 as a novel prognostic indicator for early breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  Bernard Ducommun,et al.  CDC25 phosphatases in cancer cells: key players? Good targets? , 2007, Nature Reviews Cancer.

[22]  M. Duffy,et al.  Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. , 2007, European journal of cancer.

[23]  S. Inoue,et al.  Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor , 2007, Cancer science.

[24]  S. Dudoit,et al.  Prognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling , 2007, Oncogene.

[25]  D. Roukos,et al.  Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer , 2007, Cancer biology & therapy.

[26]  N. Kasabov,et al.  Multiple Gene Expression Classifiers from Different Array Platforms Predict Poor Prognosis of Colorectal Cancer , 2007, Clinical Cancer Research.

[27]  Daniel F Hayes,et al.  ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Kathleen M Murphy,et al.  [Clinicopathological features and types of microsatellite instability in 1394 patients with colorectal cancer]. , 2020, Nan fang yi ke da xue xue bao = Journal of Southern Medical University.

[29]  P. Loehrer.  Colon Cancer Survival Rates With the New American Joint Committee on Cancer Sixth Edition Staging , 2006 .

[30]  T. Sakai,et al.  A new cancer diagnostic system based on a CDK profiling technology. , 2005, Biochimica et biophysica acta.

[31]  J. Astola,et al.  Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer. , 2005, Gastroenterology.

[32]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[33]  吉田 武史.  The clinical significance of cyclin B1 and Wee1 expression in non-small-cell lung cancer , 2005 .

[34]  C. Ko,et al.  Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. , 2005, Journal of the National Cancer Institute.

[35]  M. Peters,et al.  Prognostic value of cell cycle regulator molecules in surgically resected stage I and II breast cancer. , 2004, Oncology reports.

[36]  Daniel J Sargent,et al.  Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  H. Kuwano,et al.  The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  T. Delozier,et al.  Proliferative activity in primary breast carcinomas is a salient prognostic factor , 2004, Cancer.

[39]  N. Petrelli,et al.  Molecular prognostics in colorectal cancer. , 2003, Surgical oncology.

[40]  M. Duffy,et al.  Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. , 2003, European journal of cancer.

[41]  M. Heatley.  Epithelioid microgranulomas after Pentostatin therapy in hairy cell leukaemia , 2002, Histopathology.

[42]  K. Gatter,et al.  Ki67 protein: the immaculate deception? , 2002, Histopathology.

[43]  D. Korenaga,et al.  The relationship between cyclin B1 overexpression and lymph node metastasis in human colorectal cancer. , 2002, Surgery.

[44]  M. Daidone,et al.  Prognostic and predictive role of proliferation indices in adjuvant therapy of breast cancer. , 2001, Journal of the National Cancer Institute. Monographs.

[45]  J. Bergh,et al.  Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  F. Khuri,et al.  Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. , 2000, Cancer research.

[47]  M Monden,et al.  Overexpression of CDC25B phosphatase as a novel marker of poor prognosis of human colorectal carcinoma. , 2000, Cancer research.

[48]  P. V. van Diest,et al.  Cyclin D2 overexpression and lack of p27 correlate positively and cyclin E inversely with a poor prognosis in gastric cancer cases. , 2000, The American journal of pathology.

[49]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[50]  M. Monden,et al.  Overexpression of CDC 25 B Phosphatase as a Novel Marker of Poor Prognosis of Human Colorectal Carcinoma 1 , 2000 .

[51]  M. Furihata,et al.  Determination of the prognostic significance of cyclin B1 overexpression in patients with esophageal squamous cell carcinoma , 1999, Virchows Archiv.

[52]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[53]  S. Gansauge,et al.  Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. , 1997, Cancer research.

[54]  P. V. van Diest,et al.  Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. , 1997, The American journal of pathology.

[55]  I. Weinstein,et al.  Expression of cyclins D1 and E in human colon adenocarcinomas. , 1997, Journal of medicine.

[56]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[57]  F. A. Coller,et al.  THE PROGNOSTIC SIGNIFICANCE OF DIRECT EXTENSION OF CARCINOMA OF THE COLON AND RECTUM , 1954, Annals of surgery.